查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947908

个人化癌症疫苗市场分析及预测（至2035年）：按类型、产品、服务、技术、适应症、流程、最终用户、组件和部署类型划分

Personalized Cancer Vaccines Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Process, End User, Component, Deployment
出版日期: | 出版商: Global Insight Services | 英文 376 Pages | 商品交期: 3-5个工作天内

价格
简介目录

个人化癌症疫苗市场预计将从2024年的3.127亿美元成长到2034年的9.287亿美元，复合年增长率约为11.7%。个人化癌症疫苗市场涵盖旨在诱导患者针对癌细胞产生独特免疫反应的客製化免疫疗法。这些疫苗利用独特的肿瘤抗原，并结合基因测序和生物资讯学的最新进展而开发。癌症发病率的不断上升以及对精准医疗的需求推动了市场成长，精准医疗旨在提高疗效并减少与传统治疗方法相比的副作用。疫苗递送和佐剂技术的创新进一步促进了市场成长，为个人化癌症治疗带来了广阔的前景。

个人化癌症疫苗市场正经历强劲成长，这主要得益于免疫疗法和个人化医疗的进步。基于新抗原的疫苗占据主导地位，提供高度特异性和高效的癌症治疗方案。该领域能够根据个别患者的具体情况量身定制治疗方案，是其关键驱动因素。树突细胞疫苗表现出色，充分发挥了其刺激强效免疫反应的潜力。癌症患者数量的不断增长以及对精准标靶治疗方法日益增长的需求推动了市场需求。辅助性治疗，特别是与查核点抑制剂合併使用，正日益受到关注，以增强疫苗的疗效。虽然单药疗法仍然重要，但联合治疗正逐渐成为最大化治疗效果的首选策略。基因组学和生物资讯学的技术进步至关重要，能够识别新的目标并改进疫苗设计。预计该产业对研发的重视将带来创新解决方案，进一步推动市场成长，并为相关人员创造盈利机会。

市场区隔
类型 自体疫苗​​、异体疫苗
产品 胜肽类疫苗、树突细胞疫苗、DNA疫苗、RNA疫苗
服务 契约製造、临床试验服务、咨询服务、法规服务
科技 次世代定序、生物资讯学、人工智慧、机器学习
适应症 乳癌、肺癌、黑色素瘤、摄护腺癌、结肠癌
过程 临床前开发、临床开发、商业化
最终用户 医院、癌症研究机构、生技公司、学术机构
成分 抗原、佐剂和递送系统
实施表格 本机部署、云端部署

个人化癌症疫苗市场正经历动态变化，其特点是策略性定价模式和创新产品推出。市场领导正利用具有竞争力的定价策略来巩固自身地位，而新兴企业则专注于细分领域。在基因组学研究和免疫疗法进步的推动下，新产品的大量推出进一步丰富了市场环境。北美仍然是关键区域，而亚太地区由于医疗保健投资和意识的不断提高，展现出巨大的成长潜力。个人化癌症疫苗市场的竞争异常激烈，成熟的生技公司和新兴企业都在争夺市场份额。基准分析显示，研发投资和策略合作是重点。法规结构，尤其是在美国和欧洲，决定核准流程和打入市场策略，对市场动态重大影响。市场分析强调了合规性和创新在保持竞争力方面的重要性。随着个人化医疗的日益普及，技术进步和以患者为中心的理念有望推动市场实现变革性成长。

主要趋势和驱动因素：

个人化癌症疫苗市场正经历强劲成长，这主要得益于免疫疗法和精准医疗的进步。一个关键趋势是次世代定序技术的日益普及，该技术能够识别独特的肿瘤抗原并开发高度客製化的疫苗。这种精准的方法显着提高了治疗效果和患者预后。另一个趋势是生物技术公司与学术机构之间合作的加强，这促进了创新并加速了临床试验。这些伙伴关係对于克服癌症免疫疗法的复杂性至关重要。此外，监管支持和加快个人化疗法审批的日益重视，正在简化这些先进治疗方法的核准流程。全球癌症发生率的不断上升也是推动市场成长的因素，导致人们对更有效、更个人化的治疗方案的需求日益增长。此外，医疗专业人员和患者对个人化医疗的认识和接受度不断提高，也促进了市场成长。拥有完善医疗基础设施的新兴市场提供了充足的机会，为个人化癌症疫苗的引进提供了沃土。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 自我接种疫苗
    • 同源疫苗
  • 市场规模及预测：依产品划分
    • 基于胜肽的疫苗
    • 树突细胞疫苗
    • DNA疫苗
    • RNA疫苗
  • 市场规模及预测：依服务划分
    • 契约製造
    • 临床试验服务
    • 咨询服务
    • 监管服务
  • 市场规模及预测：依技术划分
    • 次世代定序
    • 生物资讯学
    • 人工智慧
    • 机器学习
  • 市场规模及预测：依指标
    • 乳癌
    • 肺癌
    • 黑色素瘤
    • 摄护腺癌
    • 大肠直肠癌
  • 市场规模及预测：依製程划分
    • 临床前开发
    • 临床开发
    • 商业化
  • 市场规模及预测：依最终用户划分
    • 医院
    • 癌症研究所
    • 生技公司
    • 学术机构
  • 市场规模及预测：依组件划分
    • 抗原
    • 佐剂
    • 配送系统
  • 市场规模及预测：依实施类型划分
    • 本地部署
    • 基于云端的

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Bio NTech
  • Moderna
  • Gritstone Oncology
  • Neon Therapeutics
  • Immunicum
  • Ultimovacs
  • Vaccibody
  • Transgene
  • Nouscom
  • Agenus
  • Agen Tus Therapeutics
  • Onco Sec Medical
  • Inovio Pharmaceuticals
  • Hookipa Pharma
  • Aduro Biotech
  • Cure Vac
  • Genexine
  • Onco Pep
  • Vaximm
  • e The RNA Immunotherapies

第九章：关于我们

简介目录
Product Code: GIS11048

Personalized Cancer Vaccines Market is anticipated to expand from $312.7 million in 2024 to $928.7 million by 2034, growing at a CAGR of approximately 11.7%. The Personalized Cancer Vaccines Market encompasses tailored immunotherapies designed to elicit a patient-specific immune response against cancer cells. These vaccines are developed using unique tumor antigens, leveraging advancements in genomic sequencing and bioinformatics. The market is driven by the increasing prevalence of cancer and the demand for precision medicine, aiming to improve efficacy and reduce side effects compared to conventional treatments. Innovations in vaccine delivery and adjuvant technologies further propel market growth, offering promising prospects for individualized cancer care.

The Personalized Cancer Vaccines Market is experiencing robust growth, fueled by advancements in immunotherapy and personalized medicine. The neoantigen-based vaccines segment is leading, offering highly specific and effective cancer treatments. This segment's ability to tailor therapies to individual patient profiles is a key driver. Dendritic cell vaccines follow as the second-highest performing segment, leveraging their potential to stimulate a strong immune response. The increasing prevalence of cancer and the need for precise, targeted therapies are propelling demand. Adjuvant therapies, enhancing vaccine efficacy, are gaining traction, particularly in combination with checkpoint inhibitors. Monotherapy approaches remain significant, yet combination therapies are emerging as a preferred strategy, maximizing therapeutic outcomes. Technological advancements in genomics and bioinformatics are crucial, enabling the identification of novel targets and refining vaccine design. The industry's focus on research and development is expected to yield innovative solutions, further driving market growth and presenting lucrative opportunities for stakeholders.

Market Segmentation
TypeAutologous Vaccines, Allogeneic Vaccines
ProductPeptide-Based Vaccines, Dendritic Cell Vaccines, DNA Vaccines, RNA Vaccines
ServicesCustom Manufacturing, Clinical Trial Services, Consulting Services, Regulatory Services
TechnologyNext-Generation Sequencing, Bioinformatics, Artificial Intelligence, Machine Learning
ApplicationBreast Cancer, Lung Cancer, Melanoma, Prostate Cancer, Colorectal Cancer
ProcessPreclinical Development, Clinical Development, Commercialization
End UserHospitals, Cancer Research Institutes, Biotechnology Companies, Academic Institutes
ComponentAntigens, Adjuvants, Delivery Systems
DeploymentOn-Premises, Cloud-Based

The Personalized Cancer Vaccines Market is witnessing a dynamic shift, characterized by strategic pricing models and innovative product launches. Market leaders are leveraging competitive pricing strategies to enhance their foothold, while emerging players focus on niche segments. The landscape is enriched by a surge in new product introductions, driven by advancements in genomic research and immunotherapy. North America remains a pivotal region, with Asia-Pacific showing remarkable growth potential due to increasing healthcare investments and awareness. Competition in the Personalized Cancer Vaccines Market is intense, with established biotech firms and startups vying for market share. Benchmarking reveals a focus on R&D investments and strategic collaborations. Regulatory frameworks, particularly in the United States and Europe, significantly influence market dynamics, dictating approval processes and market entry strategies. The market analysis underscores the importance of regulatory compliance and innovation in staying competitive. As personalized medicine gains traction, the market is poised for transformative growth, driven by technological advancements and patient-centric approaches.

Geographical Overview:

The personalized cancer vaccines market is gaining momentum globally, with regional dynamics shaping its growth trajectory. North America leads the market, driven by advanced healthcare infrastructure and substantial investments in personalized medicine. The United States, in particular, is at the forefront, with numerous clinical trials and strong support from research institutions. Europe follows, with robust regulatory frameworks and significant funding for cancer research, particularly in countries like Germany and the United Kingdom. In Asia Pacific, the market is expanding rapidly, powered by technological advancements and increasing awareness of personalized therapies. China and Japan are emerging as key players, investing heavily in biotechnology and healthcare innovation. Latin America presents promising growth opportunities, with Brazil spearheading efforts to integrate personalized medicine into its healthcare system. Meanwhile, the Middle East & Africa are recognizing the potential of personalized cancer vaccines, with the UAE and South Africa making strides in healthcare modernization and research initiatives.

The Personalized Cancer Vaccines Market is poised for transformation amidst global tariff impacts and geopolitical tensions. Japan and South Korea are navigating trade barriers by enhancing domestic biotech capabilities, while China accelerates its focus on homegrown biopharmaceutical innovations in response to export limitations. Taiwan's strategic position in biotech manufacturing makes it a pivotal player, though its geopolitical vulnerability remains a concern. Globally, the parent oncology market is experiencing robust growth, driven by technological advancements and rising cancer prevalence. By 2035, the market is expected to witness significant expansion, contingent on resilient supply chains and strategic collaborations. Middle East conflicts exert pressure on global energy prices, indirectly affecting production costs and logistics for biopharma companies, thereby influencing market dynamics and strategic planning.

Key Trends and Drivers:

The personalized cancer vaccines market is experiencing robust growth, propelled by advancements in immunotherapy and precision medicine. A key trend is the increasing use of next-generation sequencing technologies, which enable the identification of unique tumor antigens, leading to the development of highly tailored vaccines. This precision approach is significantly enhancing treatment efficacy and patient outcomes. Another trend is the growing collaboration between biotechnology companies and academic institutions, fostering innovation and accelerating clinical trials. These partnerships are crucial in overcoming the complexities of cancer immunotherapy. Moreover, there is a rising emphasis on regulatory support and fast-tracking of personalized therapies, which is streamlining the approval processes for these advanced treatments. The market is also driven by the increasing prevalence of cancer globally, necessitating more effective and personalized treatment options. Furthermore, the expanding awareness and acceptance of personalized medicine among healthcare professionals and patients are contributing to market growth. Opportunities abound in emerging markets where healthcare infrastructure development is underway, offering a fertile ground for the adoption of personalized cancer vaccines.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Process
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Component
  • 2.9 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Autologous Vaccines
    • 4.1.2 Allogeneic Vaccines
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Peptide-Based Vaccines
    • 4.2.2 Dendritic Cell Vaccines
    • 4.2.3 DNA Vaccines
    • 4.2.4 RNA Vaccines
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Custom Manufacturing
    • 4.3.2 Clinical Trial Services
    • 4.3.3 Consulting Services
    • 4.3.4 Regulatory Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Bioinformatics
    • 4.4.3 Artificial Intelligence
    • 4.4.4 Machine Learning
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lung Cancer
    • 4.5.3 Melanoma
    • 4.5.4 Prostate Cancer
    • 4.5.5 Colorectal Cancer
  • 4.6 Market Size & Forecast by Process (2020-2035)
    • 4.6.1 Preclinical Development
    • 4.6.2 Clinical Development
    • 4.6.3 Commercialization
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Cancer Research Institutes
    • 4.7.3 Biotechnology Companies
    • 4.7.4 Academic Institutes
  • 4.8 Market Size & Forecast by Component (2020-2035)
    • 4.8.1 Antigens
    • 4.8.2 Adjuvants
    • 4.8.3 Delivery Systems
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-Premises
    • 4.9.2 Cloud-Based

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Process
      • 5.2.1.7 End User
      • 5.2.1.8 Component
      • 5.2.1.9 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Process
      • 5.2.2.7 End User
      • 5.2.2.8 Component
      • 5.2.2.9 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Process
      • 5.2.3.7 End User
      • 5.2.3.8 Component
      • 5.2.3.9 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Process
      • 5.3.1.7 End User
      • 5.3.1.8 Component
      • 5.3.1.9 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Process
      • 5.3.2.7 End User
      • 5.3.2.8 Component
      • 5.3.2.9 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Process
      • 5.3.3.7 End User
      • 5.3.3.8 Component
      • 5.3.3.9 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Process
      • 5.4.1.7 End User
      • 5.4.1.8 Component
      • 5.4.1.9 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Process
      • 5.4.2.7 End User
      • 5.4.2.8 Component
      • 5.4.2.9 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Process
      • 5.4.3.7 End User
      • 5.4.3.8 Component
      • 5.4.3.9 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Process
      • 5.4.4.7 End User
      • 5.4.4.8 Component
      • 5.4.4.9 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Process
      • 5.4.5.7 End User
      • 5.4.5.8 Component
      • 5.4.5.9 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Process
      • 5.4.6.7 End User
      • 5.4.6.8 Component
      • 5.4.6.9 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Process
      • 5.4.7.7 End User
      • 5.4.7.8 Component
      • 5.4.7.9 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Process
      • 5.5.1.7 End User
      • 5.5.1.8 Component
      • 5.5.1.9 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Process
      • 5.5.2.7 End User
      • 5.5.2.8 Component
      • 5.5.2.9 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Process
      • 5.5.3.7 End User
      • 5.5.3.8 Component
      • 5.5.3.9 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Process
      • 5.5.4.7 End User
      • 5.5.4.8 Component
      • 5.5.4.9 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Process
      • 5.5.5.7 End User
      • 5.5.5.8 Component
      • 5.5.5.9 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Process
      • 5.5.6.7 End User
      • 5.5.6.8 Component
      • 5.5.6.9 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Process
      • 5.6.1.7 End User
      • 5.6.1.8 Component
      • 5.6.1.9 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Process
      • 5.6.2.7 End User
      • 5.6.2.8 Component
      • 5.6.2.9 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Process
      • 5.6.3.7 End User
      • 5.6.3.8 Component
      • 5.6.3.9 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Process
      • 5.6.4.7 End User
      • 5.6.4.8 Component
      • 5.6.4.9 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Process
      • 5.6.5.7 End User
      • 5.6.5.8 Component
      • 5.6.5.9 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Bio NTech
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Moderna
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Gritstone Oncology
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Neon Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Immunicum
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Ultimovacs
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Vaccibody
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Transgene
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Nouscom
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Agenus
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Agen Tus Therapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Onco Sec Medical
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Inovio Pharmaceuticals
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Hookipa Pharma
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Aduro Biotech
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Cure Vac
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Genexine
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Onco Pep
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Vaximm
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 e The RNA Immunotherapies
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us